Pharming Group N.V.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pharming Group N.V. (Euronext Amsterdam: PHARM; Nasdaq: PHAR) is a global biopharmaceutical company focused on developing and commercializing protein replacement therapies and precision medicines for rare, debilitating, and life-threatening diseases; its lead products include RUCONEST (recombinant human C1 esterase inhibitor) for treatment of acute hereditary angioedema attacks in adult and adolescent patients, and Joenja (leniolisib), an oral small molecule PI3Kδ inhibitor for activated phosphoinositide 3-kinase delta syndrome in adults and adolescents; the company advances a pipeline featuring investigational assets such as OTL-105, an ex-vivo autologous hematopoietic stem cell gene therapy for hereditary angioedema in collaboration with Orchard Therapeutics, and KL1333, a late-stage candidate for mitochondrial DNA-driven primary mitochondrial diseases acquired via the completed takeover of Abliva AB. Founded in 1988 and headquartered in Leiden, the Netherlands, with U.S. operations in Warren, New Jersey, Pharming serves patients across more than 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific through dedicated commercial infrastructure including sales forces, market access teams, patient support programs, and medical affairs. Recent developments include the December 2024 announcement and subsequent completion of the US$66.1 million acquisition of Abliva AB, adding KL1333 to the pipeline with initiation of a second wave of recruitment for its pivotal FALCON trial; full-year 2024 revenues rose 21% to US$297.2 million, driven by record RUCONEST sales and strong Joenja performance; appointment of Fabrice Chouraqui as Chief Executive Officer in March 2025; and ongoing efforts to expand leniolisib label to pediatrics, launch in additional ex-U.S. markets, and pursue value-accretive in-licensing or acquisitions in immunology, hematology, and other rare disease areas.
Pharming Group announces results of 2026 Annual General Meeting of Shareholders
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
Pharming Group: Crossing From Speculation To Profitability
Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS
Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript
European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug
Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript
Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval